Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Latest public offering nets $601mm for bluebird bio

Executive Summary

Immunotherapy and gene editing firm bluebird bio Inc. netted $601mm through the public offering of 3.9mm common shares (including the overallotment) at $162.50. Proceeds are earmarked for the following: future development of a gene therapy for severe sickle cell disease; the company's portion of development, manufacturing, and commercialization costs related to multiple myeloma CART therapy bb2121, in partnership with Celgene; Phase I study of bb21217, also for multiple myeloma and part of the Celgene agreement; Phase III trial of LentiGlobin candidate HGB212 for transfusion-dependent beta-thalassemia; continued advancement of the company's commercial infrastructure to support upcoming product launches in the US and Europe; and for ongoing manufacturing and R&D needs.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies